Preclinical data validate BBI-940's novel mechanism in a high-unmet-need population (ecDNA+ cancers). While still early, this could reprice BOLD shares if the Phase 1 trial shows signs of clinical activity. Monitor for dose escalation updates and biomarker responses from KOMODO-1 trial in 2026–2027.
Price Chart
Executive Summary
Boundless Bio (BOLD) announced preclinical data for its lead candidate BBI-940, a novel oral kinesin degrader targeting extrachromosomal DNA (ecDNA)-positive cancers, presented at AACR 2026. The data show potent antitumor activity in breast cancer models, supporting ongoing Phase 1 trials in ER+/HER2- and TNBC-LAR subtypes.
Key Facts
- Presented preclinical data at AACR 2026 demonstrating BBI-940's mechanism: selective degradation of a novel kinesin target disrupts ecDNA segregation and causes tumor cell death.
- BBI-940 showed 32% sensitivity in breast cancer cell lines, including those with ecDNA and FGFR1 gain.
- In vivo data show monotherapy tumor regressions in ecDNA+ TNBC-LAR models and strong combination activity in ecDNA+/FGFR1+ ER+ models.
- BBI-940 is currently in Phase 1 KOMODO-1 trial (NCT07408089) in advanced/metastatic breast cancer patients.
- No human efficacy or safety data reported yet — still early-stage development.
Financial Impact
Non-dilutive, preclinical-stage catalyst with potential to increase valuation if clinical data de-risk development
Risk Factors
- Early-stage development: Phase 1 trial ongoing with no clinical data yet — high risk of failure.
- Novel target and mechanism: unproven in humans, potential for unexpected toxicity or lack of efficacy.
- Low market cap ($37M): high volatility, sensitive to clinical updates and financing needs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276505 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 425 | — | awaiting T+20 | — | — |
Oct 8, 2026 17d ago | S-4 | $2.53 | awaiting T+20 | — | $2.40 (+5.14%) |
Aug 28, 2026 8w ago | 425 / 8-K | $2.81 $2.56 | ▼ −8.90% | ▼ −8.53% | $2.40 (−14.59%) |
Jul 8, 2026 15w ago | Insider Cluster | $2.51 $2.84 | ▲ +13.15% | ▲ +10.91% | $2.40 (−4.38%) |
Jul 6, 2026 15w ago | Insider Cluster | $2.50 $2.71 | ▲ +8.20% | ▲ +5.04% | $2.40 (−4.00%) |
Jun 29, 2026 16w ago | 3 | $2.50 $2.48 | ▼ −0.80% | ▲ +0.23% | $2.40 (−4.00%) |
May 8, 2026 24w ago | 8-K | $1.44 $1.42 | ▼ −1.39% | ▼ −1.41% | $2.40 (+66.67%) |
May 8, 2026 24w ago | Press Release | $1.44 $1.42 | ▲ +1.39% | ▲ +1.41% | $2.40 (−66.67%) |
Apr 17, 2026 27w ago | Press Release | $1.60 $1.42 | ▼ −11.25% | ▼ −15.45% | $2.40 (+50.00%) |
Apr 13, 2026 27w ago | 8-K | $1.56 $1.55 | ▲ +0.64% | ▲ +6.94% | $2.40 (−53.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers